ARQT
Arcutis Biotherapeutics, Inc.
OpenVolumeMkt capP/EEPSDiv yield
Day – 52-wk –
Expected move
InputsNext report
Last report
Largest filed tie
13F top-10 QoQ
Top fund weight
Arcutis Biotherapeutics has 2 disclosed suppliers and 3 disclosed customers in SEC filings.
Last report1 of 8 at or beyond impliedshaded = implied▲▼ = realized× = |realized| ÷ implied
Expected move
Inputsspot 32.07exp Nov 20ATM strike 32.5ATM straddle 4.95IV 80%
−2.47%
vs ±10.2% implied · ×0.24
shaded = implied · ▲▼ = realized
SentenceIn January 2018, we entered into an exclusive option and license agreement (the Hengrui License Agreement) with Jiangsu Hengrui Medicine Co., Ltd (Hengrui), whereby Hengrui granted us an exclusive option to obtain certain exclusive rights to research, develop, and commercialize products containing the compound designated by Hengrui as ivarmacitinib, a potent and selective JAK1 inhibitor, in topical formulations for the treatment of skin diseases, disorders, and conditions (the Hengrui Field), in the United States, Japan, United Kingdom, and the European Union (the Territory).
ARQT 10-Kaccession 0001787306-26-000018
SentenceIn August 2023, we entered into a strategic collaboration and licensing agreement (the Huadong Agreement) for topical roflumilast in Greater China and Southeast Asia with Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. (Huadong).
ARQT 10-Kaccession 0001787306-26-000018
SentenceIn July 2024, we entered into a promotion agreement with Kowa Pharmaceuticals America, Inc. (Kowa) to leverage Kowa's primary care sales force to exclusively market and promote ZORYVE in the United States to primary care practitioners and pediatricians for all FDA-approved indications until at least July 2029.
ARQT 10-Kaccession 0001787306-26-000018
SentenceIn February 2024, we entered into a a strategic collaboration and licensing agreement (the Sato Agreement) for topical roflumilast in Japan with Sato Pharmaceutical Co., Ltd.(Sato).
ARQT 10-Kaccession 0001787306-26-000018
Arcutis Biotherapeutics, Inc.
32.03
+0.06 · +0.18%
post 31.90 −0.40%
Linked news
News